Elite in Becker Muscular Dystrophy

Dr. Erika L. Finanger

Pediatric Neurology | Pediatrics | Neurology
University Professional Services
3181 Sw Sam Jackson Park Rd, 
Portland, OR 
Accepting New Patients
Elite in Becker Muscular Dystrophy
University Professional Services
3181 Sw Sam Jackson Park Rd, 
Portland, OR 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Erika Finanger is a Pediatric Neurologist and a Pediatrics provider in Portland, Oregon. Dr. Finanger and is rated as an Elite provider by MediFind in the treatment of Becker Muscular Dystrophy. Her top areas of expertise are Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Cramp-Fasciculation Syndrome, and Primary Lateral Sclerosis. Dr. Finanger is currently accepting new patients.

Her clinical research consists of co-authoring 26 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 16 articles and participated in 13 clinical trials in the study of Becker Muscular Dystrophy.

Specialties
Pediatric Neurology
Pediatrics
Neurology
Licenses
Neurology with Special Qualifications in Neurology in MD
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

BridgeSpan
  • EPO
  • HMO
Moda Health
  • EPO
  • PPO
PacificSource
  • PPO
Prominence Health
  • EPO
  • PPO
Regence
  • EPO
  • PPO

Locations

UNIVERSITY PROFESSIONAL SERVICES
3181 Sw Sam Jackson Park Rd, Portland, OR 97239
Other Locations
UNIVERSITY PROFESSIONAL SERVICES
15700 Sw Greystone Ct, Beaverton, OR 97006

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Intravenous Delivery of Allogeneic Cardiosphere-Derived Cells in Subjects With Duchenne Muscular Dystrophy
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Intravenous Delivery of Allogeneic Cardiosphere-Derived Cells in Subjects With Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: May 28, 2025
Intervention Type: Drug, Biological
Study Phase: Phase 2
A Double-Blind, Placebo-Controlled, Multi-Center Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy
A Double-Blind, Placebo-Controlled, Multi-Center Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy
Enrollment Status: Active_not_recruiting
Publish Date: December 16, 2024
Intervention Type: Drug
Study Drugs: SRP-4045 Exon 45-Skipping Treatment, SRP-4053 Exon 53-Skipping Treatment
Study Phase: Phase 3
A Phase 3 Multinational, Randomized, Double-Blind, Placebo-Controlled Systemic Gene Delivery Study to Evaluate the Safety and Efficacy of SRP-9001 in Subjects With Duchenne Muscular Dystrophy (EMBARK)
A Phase 3 Multinational, Randomized, Double-Blind, Placebo-Controlled Systemic Gene Delivery Study to Evaluate the Safety and Efficacy of SRP-9001 in Subjects With Duchenne Muscular Dystrophy (EMBARK)
Enrollment Status: Completed
Publish Date: December 10, 2024
Intervention Type: Genetic
Study Phase: Phase 3
Trial of Pamrevlumab (FG-3019), a Monoclonal Antibody to Connective Tissue Growth Factor, in Non-Ambulatory Subjects With Duchenne Muscular Dystrophy
Trial of Pamrevlumab (FG-3019), a Monoclonal Antibody to Connective Tissue Growth Factor, in Non-Ambulatory Subjects With Duchenne Muscular Dystrophy
Enrollment Status: Terminated
Publish Date: August 27, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 2
A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)
A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)
Enrollment Status: Terminated
Publish Date: August 26, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
A Phase 3, Randomized, Double-Blind Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Subjects With Non-ambulatory Duchenne Muscular Dystrophy (DMD)
A Phase 3, Randomized, Double-Blind Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Subjects With Non-ambulatory Duchenne Muscular Dystrophy (DMD)
Enrollment Status: Terminated
Publish Date: March 12, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
A Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy and Open-Label Extension
A Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy and Open-Label Extension
Enrollment Status: Completed
Publish Date: January 18, 2024
Intervention Type: Drug
Study Drug: Ataluren
Study Phase: Phase 3
Randomised, Double Blind, Placebo Controlled, Multicentre Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy
Randomised, Double Blind, Placebo Controlled, Multicentre Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: February 02, 2023
Intervention Type: Drug
Study Drug: Givinostat
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Global Phase 3 Study of Edasalonexent in Pediatric Patients With Duchenne Muscular Dystrophy
A Randomized, Double-Blind, Placebo-Controlled, Global Phase 3 Study of Edasalonexent in Pediatric Patients With Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: June 21, 2022
Intervention Type: Drug
Study Phase: Phase 3
An Open-Label, Multi-Center, Study With a Concurrent Untreated Control Arm to Evaluate the Efficacy and Safety of Eteplirsen in Duchenne Muscular Dystrophy
An Open-Label, Multi-Center, Study With a Concurrent Untreated Control Arm to Evaluate the Efficacy and Safety of Eteplirsen in Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: January 25, 2021
Intervention Type: Drug
Study Phase: Phase 3
An Open-Label, Multi-Center Study to Evaluate the Safety, Efficacy and Tolerability of Eteplirsen in Early Stage Duchenne Muscular Dystrophy
An Open-Label, Multi-Center Study to Evaluate the Safety, Efficacy and Tolerability of Eteplirsen in Early Stage Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: January 25, 2021
Intervention Type: Drug
Study Phase: Phase 2
Phaseout DMD: A Phase 2 Clinical Study to Assess the Activity and Safety of Utrophin Modulation With Ezutromid in Ambulatory Paediatric Male Subjects With Duchenne Muscular Dystrophy (SMT C11005)
Phaseout DMD: A Phase 2 Clinical Study to Assess the Activity and Safety of Utrophin Modulation With Ezutromid in Ambulatory Paediatric Male Subjects With Duchenne Muscular Dystrophy (SMT C11005)
Enrollment Status: Terminated
Publish Date: January 02, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 11 Less Clinical Trials

26 Total Publications

Characterization of severe COL6-related dystrophy due to the recurrent variant COL6A1 c.930+189C>T.
Characterization of severe COL6-related dystrophy due to the recurrent variant COL6A1 c.930+189C>T.
Journal: Brain : a journal of neurology
Published: October 03, 2024
Similar Doctors
Advanced in Becker Muscular Dystrophy
Dr. Barry S. Russman
Pediatric Neurology
Advanced in Becker Muscular Dystrophy
Dr. Barry S. Russman
Pediatric Neurology
3181 Sw Sam Jackson Park Rd, 
Portland, OR 
 (0.1 mi)
503-494-5856
Languages Spoken:
English
See accepted insurances

Barry Russman is a Pediatric Neurologist in Portland, Oregon. Dr. Russman and is rated as an Advanced provider by MediFind in the treatment of Becker Muscular Dystrophy. His top areas of expertise are Becker Muscular Dystrophy, Duchenne Muscular Dystrophy, and Primary Lateral Sclerosis.

Experienced in Becker Muscular Dystrophy
Dr. Nizar S. Chahin
Neurology
Experienced in Becker Muscular Dystrophy
Dr. Nizar S. Chahin
Neurology

University Professional Services

3181 Sw Sam Jackson Park Rd, 
Portland, OR 
 (0.1 mi)
503-494-8311
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Nizar Chahin is a Neurologist in Portland, Oregon. Dr. Chahin and is rated as a Distinguished provider by MediFind in the treatment of Becker Muscular Dystrophy. His top areas of expertise are Inclusion Body Myositis, Myasthenia Gravis, Nemaline Myopathy, and Lambert-Eaton Syndrome. Dr. Chahin is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Finanger's expertise for a condition
ConditionClose
    View All 14 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile